These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

659 related items for PubMed ID: 9295170

  • 1. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.
    Braun AR, Laruelle M, Mouradian MM.
    J Neural Transm (Vienna); 1997; 104(4-5):341-62. PubMed ID: 9295170
    [Abstract] [Full Text] [Related]

  • 2. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT, White FJ.
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [Abstract] [Full Text] [Related]

  • 3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT, White FJ.
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [Abstract] [Full Text] [Related]

  • 4. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.
    Marin C, Parashos SA, Kapitzoglou-Logothetis V, Peppe A, Chase TN.
    Pharmacol Biochem Behav; 1993 May; 45(1):195-200. PubMed ID: 8516358
    [Abstract] [Full Text] [Related]

  • 5. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H, Gerlach J, Peacock L.
    Psychopharmacology (Berl); 1993 May; 112(2-3):389-97. PubMed ID: 7871047
    [Abstract] [Full Text] [Related]

  • 6. D1-D2 dopamine receptor synergy in striatum: effects of intrastriatal infusions of dopamine agonists and antagonists on immediate early gene expression.
    Keefe KA, Gerfen CR.
    Neuroscience; 1995 Jun; 66(4):903-13. PubMed ID: 7651617
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Concurrent activation of dopamine D1 and D2 receptors is required to evoke neural and behavioral phenotypes of cocaine sensitization.
    Capper-Loup C, Canales JJ, Kadaba N, Graybiel AM.
    J Neurosci; 2002 Jul 15; 22(14):6218-27. PubMed ID: 12122080
    [Abstract] [Full Text] [Related]

  • 9. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA.
    J Pharmacol Exp Ther; 1987 Jan 15; 240(1):167-76. PubMed ID: 3100767
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction.
    Garrett BE, Holtzman SG.
    Eur J Pharmacol; 1994 Sep 01; 262(1-2):65-75. PubMed ID: 7813580
    [Abstract] [Full Text] [Related]

  • 12. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ, Albers LJ, Le H, Creese I.
    J Pharmacol Exp Ther; 1986 Sep 01; 238(3):846-54. PubMed ID: 3018223
    [Abstract] [Full Text] [Related]

  • 13. Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats.
    Graham DL, Hoppenot R, Hendryx A, Self DW.
    Psychopharmacology (Berl); 2007 Apr 01; 191(3):719-30. PubMed ID: 16835769
    [Abstract] [Full Text] [Related]

  • 14. Fetal behavior and the dopamine system: activity effects of D1 and D2 receptor manipulations.
    Moody CA, Robinson SR, Spear LP, Smotherman WP.
    Pharmacol Biochem Behav; 1993 Apr 01; 44(4):843-50. PubMed ID: 8097042
    [Abstract] [Full Text] [Related]

  • 15. Dopaminergic and cholinergic interaction in cataleptic responses in mice.
    Ushijima I, Kawano M, Kaneyuki H, Suetsugi M, Usami K, Hirano H, Mizuki Y, Yamada M.
    Pharmacol Biochem Behav; 1997 Sep 01; 58(1):103-8. PubMed ID: 9264077
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Receptor subtype-specific dopaminergic agents and unconditioned behavior.
    Beninger RJ, Mazurski EJ, Hoffman DC.
    Pol J Pharmacol Pharm; 1991 Sep 01; 43(6):507-28. PubMed ID: 1687945
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.
    Verma A, Kulkarni SK.
    Psychopharmacology (Berl); 1992 Sep 01; 109(4):477-83. PubMed ID: 1365866
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.